Loading clinical trials...
Loading clinical trials...
A Double-Blind, Randomized, Placebo-Controlled, Dose Titration Study of ANAVEX2-73 in Patients With Rett Syndrome
Conditions
Interventions
ANAVEX2-73
Placebo
Locations
8
United States
UAB | The University of Alabama at Birmingham
Birmingham, Alabama, United States
UC Davis University of California - Davis MIND Institute
Sacramento, California, United States
Rush University Medical Center
Chicago, Illinois, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Washington University in St. Louis | Saint Louis Children's Hospital
St Louis, Missouri, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Start Date
February 28, 2019
Primary Completion Date
October 30, 2020
Completion Date
October 30, 2020
Last Updated
January 12, 2021
NCT06139172
NCT06338267
NCT05740761
NCT06856759
NCT06705816
NCT04463316
Lead Sponsor
Anavex Life Sciences Corp.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions